Ms. Wang focuses her legal practice on patent and technology transactions. Ms. Wang had been working consecutively in LungTin IP firm, the Patent and Licensing Department of Novozymes China and later in AnJie Law Firm. She joined Lifang & Partners in June 2021.
Ms. Wang mainly serves technology companies, especially those in the fields of pharmaceutical, biotechnology, chemistry and chemical engineering. She represents clients in patent invalidation and infringement litigation. As a legal counsel to a number of biopharmaceutical companies, she helps the clients with patent strategy development, enterprise IP system establishment, patent prosecution, and provides clients with patent validity analysis, FTO analysis, and other patent-related matters.
In the past few years, Ms. Wang has represented many domestic companies in the negotiation of technology licensing and R&D collaboration with foreign companies and universities, covering the fields of gene editing, drug development, medical devices, cosmetics, semi-conductor and other technical fields, and helped clients draft and review contracts.
In addition to providing patent services focused on China, Ms. Wang also has a deep understanding of patent practices in major foreign jurisdictions such as the US, Europe and India. She provides clients with a global perspective on patent protection. During her nine years’ working period as an inhouse IP counsel, Ms. Wang had worked on global IP issues for several business units, including managing a series of European patent opposition and appeal cases between Novozymes and its competitors, and participating in licensing negotiations to settle Novozymes’ global IP disputes. Ms. Wang had also worked as a team member in a plenty of R&D projects, with rich experiences in patent landscape analysis, design around and IP risk management.
Representative Matters
‒ Represented Cure Genetics Co. Ltd on its R&D collaboration and licensing negotiation with Boehringer Ingelheim and reviewed its agreement;
‒ Represented IMMORNA on R&D collaboration negotiations for mRNA vaccine development and drafted the agreement;
‒ Represented WALVAX on vaccine license-in negotiation and reviewed its agreement;
‒ Advised a chemical catalysts company on technology licensing from MIT and drafted sub-license agreement;
‒ Represented a Japanese cosmetic company on technology licensing with a Chinese company and reviewed its agreement;
‒ Represented a Chinese Biotech company in license negotiation with Broad Institute on CRISPR-Cas9 patent portfolios, and reviewed its agreement;
‒ Provided opinions on IP risks in the high-speed railway technology transfer agreement;
‒ Represented a Chinese Biotech company on a R&D collaboration negotiation for CAR-T and drafted agreement;
‒ Represented a start-up biopharma company on acquiring new drug technology;
‒ Represented a U.S. company for IP due diligence in a M&A deal in China;
‒ IP consultation to a domestic pesticide company on establishment of its IP system, optimizing its internal patent filing workflow, setting up evaluation system for its patent portfolio;
‒ Drafted the book of “IP Guideline for outbound investment” for Shanghai Municipal Commission of Commerce (including patent, trademark, copyright, trade secret, IP due diligence and IP protection for trade fairs);
‒ Drafted Guidance Note for UK-China collaborative research IP toolkit (Lambert Toolkit) (including content related to IP, technology licensing, technology import and export regulation, academic publication, indemnification, arbitration, data protection, etc.); prepared the Chinese version of 11 model agreements (collaboration agreements between university and enterprise);
‒ Represented Solvay on patent infringement lawsuit against a Chinese Chemical company;
‒ Represented Personal Genomics, Inc on its patent invalidation and infringement litigation against Pacific Bioscience Inc.
‒ Representesd BISSEL on its patent invalidation and infringement litigation against Tineco;
‒ Advised a European pharma company on technology transaction dispute with a Chinese company, including litigation strategy related to trade secret infringement, IP ownership dispute and HKIAC Arbitration;
‒ Represented Philip Morris on design patent infringement lawsuits against a Chinese company;
‒ Represented FRX Polymers, Inc on administrative litigation for patent reexamination
‒ Represented Nichia on patent invalidation against a Taiwan company Everlight;
‒ Represented Novozymes on a patent infringement litigation related to alpha-amylase against local enzymes companies;
‒ Represented Novozymes on managing a series of EP opposition/appeal cases against Genencor and AB Enzymes;
‒ Represented Novozymes on patent invalidation cases against Dupont in China.
Professional Affiliations
- Member of All China Lawyers Association
- Member of All-China Patent Agents Association
- Member of LESI (Licensing Executives Society International)
- National Advisory Expert under National Advisory Center for Overseas IP Disputes Settlement
Awards
- Legal 500 Recommended Intellectual Property Lawyer 2017
Publications/Speeches
‒ “Latest Developments on Data Supplementation for Chemical or Pharmaceutical Patents in China” June 2021, Lexology
‒ “China Patent: Data supplementation for chemical and biotech patents in China” March 2018, Managing Intellectual Property.
‒ International Comparative Legal Guide: Patents 2018 (8th Edition) published in September 2017 https://iclg.com/practice-areas/patents-laws-and-regulations/china
‒ “China Patent: Patent Enforcement at Trade Fairs” October 2016, Managing Intellectual Property.
‒ “China Patent: Patent Law Amendments Cause Hope and Questions” February 2016, Managing Intellectual Property.
‒ Speech: “IP Due Diligence and its Business Implications under Different Scenarios”, September 21, 2022, 7th Pharmaceutical Intellectual Property Summit, Suzhou
‒ Speech: “Drug Patent Linkage and Patent Term Extension”, September 30, 2021, China Biological and Chemical Pharmaceutical Industry Conference, Suzhou
‒ Speech: “IP due diligence in the listing, investment, M&A of pharmaceutical enterprises”, Asia-Pacific Biomedical Cooperation Summit, Shanghai, January 21, 2021
‒ Speech: “Main legal points of technology licensing and R&D cooperation in biopharmaceutical field”, L-Counsel, webinar, October 10, 2020
‒ Speech: “Chinese bio/pharma patents: A review from validity perspective”, The 2nd Pharmaceutical Intellectual Property Summit, December 7, 2017, Shanghai
‒ Speech: “Patent strategy - empowering pharmaceutical R&D”, Asian Pharmaceutical Research and Development Leaders Summit, April 11, 2017, Shanghai
‒ Speech: “Life science focus: how to balance R&D resource and patent”, China International IP Forum organized by Managing Intellectual Property, June 12, 2014, Beijing
‒ Speech: “Freedom to Operate Analysis”, “Patent invalidation in China”, 5th Advanced China IP Counsel Forum organized by American Conference Institute, April 17, 2013, Shanghai
Education
‒ LLM, Temple University,
‒ M.Sc. in Biochemistry, Tsinghua University,
‒ B.Sc. in Biological Science and Biotechnology, Zhejiang University,
Qualifications
- China Licensed Lawyer
- China Licensed Patent Attorney
Working Languages
WANG Ying Partner +86 10 64096099 yingwang@lifanglaw.com 
download